Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is emerging muscular dystrophy agents!
Quiz|Articles|September 20, 2026 (Updated: September 17, 2026)
NeurologyLive® Brain Games: September 20, 2026
Author(s)Louie Pasculli, Marco Meglio
Listen
0:00 / 0:00
Key Takeaways
- A Sunday-release cadence structures a three-question format intended to assess breadth across major neurology subspecialties.
- Clinician- and expert-written questions integrate both clinical practice and historical context within neurological disease domains.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Parkinson disease biomarkers!
Advertisement
Welcome to NeurologyLive® Brain Games! This weekly quiz series, which goes live every Sunday morning, will feature questions on a variety of clinical and historical neurology topics, written by physicians, clinicians, and experts in the fields of neurological care and advocacy.
Test your mettle each week with 3 questions that cover a variety of aspects in the field of neurology, with a focus on dementia and Alzheimer disease, epilepsy and seizure disorders, headache and migraine, movement disorders, multiple sclerosis, neuromuscular disorders, sleep disorders, and stroke and cerebrovascular disease.
This week's questions includes the theme of Parkinson disease biomarkers!
Interested in submitting quiz questions? Contact our editor, Marco Meglio, via email:
A 67-year-old patient has bradykinesia, rigidity, and a resting tremor, but the clinical diagnosis remains uncertain. Cerebrospinal fluid testing demonstrates a positive α-synuclein seed amplification assay (αSyn-SAA). Which interpretation is most appropriate?
A neurologist is evaluating a patient with suspected Parkinson disease and is considering dopamine transporter (DAT) SPECT imaging. Which finding would most strongly support a presynaptic dopaminergic deficit?
A patient with early Parkinson disease has a positive CSF αSyn-SAA. Investigators subsequently observe that the assay remains positive over serial assessments despite clinical progression. Which statement best describes the current limitation of αSyn-SAA as a longitudinal biomarker?
How did you do on this week's quiz? Let us know with a response to the poll below. Don't forget to share and compare your results with your friends!
How many questions did you get correct?
Advertisement
Related to this article
A retrospective cohort study found DTI-ALPS, a glymphatic function marker, did not independently predict survival in glioblastoma beyond extent of resection and sex.
The approval, based on phase 3 IB1001-303 trial data showing consistent SARA scale improvement, makes levacetylleucine the first treatment approved specifically for ataxia-telangiectasia.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 18, 2026.
A published protocol outlines the randomized, open-label EPOCH trial testing whether cilostazol accelerates hematoma resorption and improves recovery after intracerebral hemorrhage.
Brian Lin, PhD, discussed the current evidence linking football participation with ALS, the questions that remain unanswered, and how emerging research may help clarify the association.
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Jennifer Fokas, MD, and Minali Nigam, MD. [LISTEN TIME: 21 minutes]
A recent MS cohort study suggests that higher EBV nuclear antigen 1 antibody levels are associated with a lower risk of confirmed disability worsening, particularly among patients carrying both HLA-A02:01 and HLA-DRB115:01.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Levacetylleucine for Ataxia-Telangiectasia
2
FDA Clears Phase 1b/2 Trial of CAR T-Cell Therapy C-CAR168 for Refractory Progressive Multiple Sclerosis
3
FDA Approves UX111, First Gene Therapy for Pediatric Sanfilippo Syndrome Type A
4
Episode 175: Advancing the Ways of Treating Cluster Headache
5